Today: 7 February 2026
Subscribe
Browse Category

Legal News News 15 December 2025 - 21 December 2025

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

As the market heads into a Christmas-shortened trading week, Johnson & Johnson (NYSE: JNJ) is entering the final stretch of 2025 with an unusually headline-heavy mix of catalysts: U.S. drug-pricing negotiations tied to the White House, new talc-related jury verdicts, and a string of FDA and clinical updates that reinforce the company’s longer-term growth narrative. As of the latest close (Friday, December 19, 2025), JNJ ended around $206/share, keeping the stock in a tight, late-year range while investors weigh whether policy risk and litigation uncertainty outweigh the steadier benefits of new product momentum and “defensive” healthcare positioning. MarketBeat Below is
21 December 2025
····
Booking Holdings (BKNG) Stock News, Forecasts, and Analysis for Dec. 20, 2025: Court Ruling Risk Meets Holiday Travel Tailwinds

Booking Holdings (BKNG) Stock News, Forecasts, and Analysis for Dec. 20, 2025: Court Ruling Risk Meets Holiday Travel Tailwinds

Booking Holdings Inc. (NASDAQ: BKNG) heads into the weekend of December 20, 2025 with investors balancing two powerful narratives: robust global travel demand and a fresh legal jolt in Europe tied to Booking.com’s historical “best price” (rate parity) clauses. As of the latest available U.S. market data (U.S. exchanges are closed on Saturday), BKNG last traded around $5,394, up roughly 0.95% from the prior close. Below is a roundup of the most relevant current news, forecasts, and market analysis shaping the Booking Holdings stock story as of 20.12.2025. BKNG stock snapshot: where Booking Holdings stands heading into the weekend BKNG
21 December 2025
····
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Dec. 20, 2025 — Johnson & Johnson (NYSE: JNJ) is closing out the week with investors weighing a fresh talc-related jury verdict, a fast-moving U.S. drug-pricing policy push that could soon reach J&J, and a stream of late-2025 catalysts spanning FDA-related updates, M&A, and a major MedTech restructuring plan. JNJ shares last traded around $206.37, down about 0.9% from the prior close, after touching higher levels earlier in the week. The bigger picture: J&J has delivered a strong 2025 run by large-cap healthcare standards, with total return measures showing roughly high‑40% year-to-date performance by mid-to-late December. Finance Charts Johnson &
20 December 2025
·····
Visa Stock News Today (NYSE: V): USDC Stablecoin Settlement, Legal Updates, and Wall Street Forecasts for 2026

Visa Stock News Today (NYSE: V): USDC Stablecoin Settlement, Legal Updates, and Wall Street Forecasts for 2026

December 20, 2025 — Visa Inc. (NYSE: V) is closing out the week with investors weighing a busy stretch of product headlines, regulatory developments, and analyst upgrades. Visa shares last traded around $349.25 on Dec. 19 (the most recent U.S. session), up 0.94% on the day, with a 52‑week range of $299.00 to $375.51, according to the company’s stock quote page. Visa Investor Relations While the calendar is moving into year-end, the story around Visa stock is still in motion: stablecoins are shifting from “disruption” to “distribution,” AI-powered commerce is moving from demos into controlled real-world transactions, and legal headlines
20 December 2025
····
Coinbase Stock (COIN) After Hours on Dec. 19, 2025: Lawsuits, Stablecoin Deals and Bitcoin Moves to Watch Before the Next Market Open

Coinbase Stock (COIN) After Hours on Dec. 19, 2025: Lawsuits, Stablecoin Deals and Bitcoin Moves to Watch Before the Next Market Open

Coinbase Global, Inc. (NASDAQ: COIN) finished Friday, Dec. 19, 2025, higher and then traded modestly in after-hours action—capping a volatile week in which crypto prices, regulatory headlines, and Coinbase’s push beyond pure crypto trading all competed for investor attention. In regular trading, COIN closed at $245.12, up 2.47%, after ranging between $240.85 and $247.00, with about 10.61 million shares traded. Investing.comAfter the closing bell, the stock was $245.78 (+0.27%) as of 6:16 p.m. ET, according to Yahoo Finance (after-hours prices can change quickly). Yahoo Finance Even with Friday’s bounce, the “why” behind Coinbase’s move is best understood as a three-part
20 December 2025
·····
Prediction Markets Surge on Dec. 19, 2025: Robinhood’s NFL “Combos,” DraftKings’ New Predictions App, Coinbase Lawsuits, and Polymarket’s Latest Turbulence

Prediction Markets Surge on Dec. 19, 2025: Robinhood’s NFL “Combos,” DraftKings’ New Predictions App, Coinbase Lawsuits, and Polymarket’s Latest Turbulence

On Friday, December 19, 2025, the fast-growing world of prediction markets—often framed as “event trading” and sometimes criticized as a backdoor to sports betting—delivered a cluster of developments that show just how quickly the category is moving from crypto niche to mainstream financial battleground. In just 24 hours, headlines ranged from DraftKings launching a standalone prediction-market product, to Coinbase suing three U.S. states over who gets to regulate event contracts, to Polymarket restoring services after a Polygon-related disruption, all while trading apps like Robinhood keep expanding sports-style contracts that look increasingly similar to parlays—only packaged as exchange-traded “yes/no” instruments. Sports
20 December 2025
·····
Ben & Jerry’s vs Magnum Ice Cream: Court Filings Warn of More Board Ousters as Foundation Fights Funding Threat (Dec. 19, 2025)

Ben & Jerry’s vs Magnum Ice Cream: Court Filings Warn of More Board Ousters as Foundation Fights Funding Threat (Dec. 19, 2025)

Ben & Jerry’s long-running battle over who controls the brand’s famously activist “social mission” escalated again this week—this time with the ice cream maker’s independent board warning a federal judge that more directors could be pushed out within days, and the Ben & Jerry’s Foundation moving to join an ongoing lawsuit after its new corporate parent signaled it could halt future funding. Reuters+1 The dispute sits at the intersection of corporate governance, brand identity, and politics—and it is now unfolding under a new owner: The Magnum Ice Cream Company (TMICC), the standalone ice cream business spun out of Unilever earlier
19 December 2025
····
Coinbase Stock (NASDAQ: COIN) News on Dec. 19, 2025: Prediction‑Market Lawsuits, “Everything Exchange” Expansion, and Wall Street Forecasts

Coinbase Stock (NASDAQ: COIN) News on Dec. 19, 2025: Prediction‑Market Lawsuits, “Everything Exchange” Expansion, and Wall Street Forecasts

December 19, 2025 Coinbase Global, Inc. (NASDAQ: COIN) is back in the spotlight on Friday as investors weigh a fresh wave of legal headlines against the company’s biggest strategic pivot in years: becoming an “everything exchange” that blends crypto, stocks, tokenized equities, and prediction markets in one app. As of 15:48 UTC on Dec. 19, COIN shares traded around $241.45, up about 0.94% on the day, after opening near $242.49 and moving in a $241.04–$247.19 intraday range. Coinbase’s market capitalization at that time was roughly $71.3 billion, with about 6.7 million shares traded. That price action may look calm, but
19 December 2025
·····
Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson (NYSE: JNJ) finished Thursday’s regular session lower even as the broader market moved higher, then ticked modestly upward in after-hours trading—leaving investors with a familiar year-end setup: solid pipeline/MedTech progress on one side, and talc litigation headlines on the other. JNJ stock price after the bell: the key numbers investors are watching tonight JNJ shares closed the regular session at $208.31, down $2.02 (-0.96%), and were slightly higher after hours at about $208.65 (+0.16%) in early evening trading. Investing.com A few additional “snapshot” metrics help frame where JNJ sits heading into Friday’s open: On a day when
19 December 2025
····
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals+2Investing.com+2 On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of roughly 6.36 million shares—a notably volatile day by recent standards. Investing.com+1 In the U.S., Telix’s Nasdaq-listed shares/ADS were also under pressure, with U.S. market coverage noting a gap-down move and a roughly 6%–7% decline in early trading action on Dec.
17 December 2025
······
Visa Stock After Hours (Dec. 15, 2025): V Holds Near $347 as Stablecoin Push Collides With Swipe-Fee Legal Fight — What to Watch Before Tuesday’s Open

Visa Stock After Hours (Dec. 15, 2025): V Holds Near $347 as Stablecoin Push Collides With Swipe-Fee Legal Fight — What to Watch Before Tuesday’s Open

Visa Inc. (NYSE: V) finished Monday’s session slightly lower, then traded essentially flat after the closing bell—ending a day where investors had to weigh two very different storylines: Visa’s fresh stablecoin initiative and a renewed legal overhang tied to U.S. “swipe fee” litigation. Reuters+3StockAnalysis+3MarketScreener+3 The broader market backdrop was cautious. Major U.S. indexes drifted down as traders positioned ahead of a key jobs report due Tuesday morning, a release that can move Treasury yields and risk sentiment—two macro inputs that often ripple into payment leaders like Visa. AP News+1 Below is a detailed, publication-ready breakdown of what happened to Visa
16 December 2025
····
Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk. On Monday, December 15, 2025, JNJ shares traded around the $214 level, brushing the upper end of their recent trading range and extending a rally that has put the healthcare bellwether sharply higher on the year. Investing.com+2MarketScreener+2 What’s moving JNJ today isn’t a single earnings surprise. Instead, it’s a high‑impact regulatory catalyst—a newly granted FDA priority voucher tied to a multiple myeloma regimen—arriving the same
15 December 2025
····
1 … 6 7 8 9 10 … 14

Stock Market Today

Stellantis stock rattled by $26.5 billion EV reset and dividend halt ahead of Monday trade

Stellantis stock rattled by $26.5 billion EV reset and dividend halt ahead of Monday trade

7 February 2026
Milan, February 7, 2026, 10:54 (CET) — Market closed. Stellantis shares (STLA) closed at $7.28 in New York on Friday, down 23.8%, after the Jeep maker unveiled a €22.2 billion ($26.5 billion) hit tied to scaling back electric-vehicle plans and said it would not pay a dividend in 2026. The selloff matters going into next week because it forces a quick rethink on cash and capital returns at a company investors once treated as a high-yield play. With markets shut for the weekend, traders will be looking for any follow-through from credit markets and analysts before Monday’s open. In Europe,
Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop